You are here

Ipsen

Ipsen, Servier announce initial phase 1/2 data of liposomal irinotecan in metastatic pancreatic cancer

Ipsen, Servier announce initial phase 1/2 data of liposomal irinotecan in metastatic pancreatic cancer

Pharmaceutical Business Review

liposomal irinotecan

pancreatic cancer

Flag link:

Biotech M&A is back. Ipsen set to fork out up to $1.3B for rare disease specialist Clementia

Biotech M&A is back. Ipsen set to fork out up to $1.3B for rare disease specialist Clementia

Endpoints

Clementia Pharmaceuticals

Flag link:

FDA approves Cabometyx for liver cancer

FDA approves Cabometyx for liver cancer

BioCentury

Flag link:

With New HQ, Ipsen to Rapidly Expand North American Presence

With New HQ, Ipsen to Rapidly Expand North American Presence

BioSpace

Flag link:

Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated Hepatocellular Carcinoma

Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated Hepatocellular Carcinoma

CP WIre

hepatocellular carcinoma

Flag link:

Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated Hepatocellular Carcinoma

hepatocellular carcinoma

Flag link:

Canada Approves Cabometyx for Adults with Previously Treated Advanced Renal Cell Carcinoma

Canada Approves Cabometyx for Adults with Previously Treated Advanced Renal Cell Carcinoma

CP Wire

renal cell carcinoma

Flag link:

Canada Approves Cabometyx for Adults with Previously Treated Advanced Renal Cell Carcinoma

Flag link:

Relocating its US HQ to Boston, French pharma Ipsen to add 250 jobs

Relocating its US HQ to Boston, French pharma Ipsen to add 250 jobs

Endpoints

Flag link:

Exelixis and Ipsen Announce European Approval of Cabometyx for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma

advanced renal cell carcinoma

renal cell carcinoma

Flag link:

Ipsen focuses on oncology to keep growing

Ipsen focuses on oncology to keep growing

GoInPharma

Flag link:

Ipsen wins approval for gastroenteropancreatic neuroendocrine tumor drug

Ipsen wins approval for gastroenteropancreatic neuroendocrine tumor drug

Mass Device

gastroenteropancreatic neuroendocrine tumor

Flag link:

Sanofi Sells 5 Over-the-Counter Drugs for $88M

Sanofi Sells 5 Over-the-Counter Drugs for $88M

Investopedia

Flag link:

France's Ipsen to buy Merrimack's pancreatic cancer drug, assets in $1 bln deal

France's Ipsen to buy Merrimack's pancreatic cancer drug, assets in $1 bln deal

Yahoo/Reuters

Merrimack Pharmaceuticals

pancreatic cancer

Flag link:

Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX™ (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO

Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX™ (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO

Yahoo

clinical trials

advanced renal cell carcinoma

Flag link:

Ipsen to Step Up Deal-Making, Scout for New Cancer Products

Ipsen to Step Up Deal-Making, Scout for New Cancer Products

Bloomberg

Flag link:

Ipsen on a hiring binge in U.S. to prep for new Somatuline marketing push

Ipsen on a hiring binge in U.S. to prep for new Somatuline marketing push

Fierce Pharma Marketing

Flag link:

Nestle’s Galderma Deepens Ipsen Alliance for Wrinkle Smoother

Nestle’s Galderma Deepens Ipsen Alliance for Wrinkle Smoother

Bloomberg

Flag link:

China Drug Probe Leads to Tougher Market, Ipsen CEO Says

China Drug Probe Leads to Tougher Market, Ipsen CEO Says

Bloomberg

Flag link:

Baxter snags hemophilia candidate in $185M deal with Ipsen and broke biotech

Baxter snags hemophilia candidate in $185M deal with Ipsen and broke biotech

Fierce Biotech

Baxter International

Flag link:

Pages